JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Romagnoli, S.
Right arrow Articles by Sorbara, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Romagnoli, S.
Right arrow Articles by Sorbara, C.
Related Collections
Right arrow Blood
Right arrow Heart
Right arrow Monitoring (Cardiac)

Anesth Analg 2006;102:1320-1326
© 2006 International Anesthesia Research Society
doi: 10.1213/01.ane.0000209023.96418.e5


CARDIOVASCULAR ANESTHESIA

Small-Dose Recombinant Activated Factor VII (NovoSeven®) in Cardiac Surgery

Stefano Romagnoli, MD, Sergio Bevilacqua, MD*, Sandro Gelsomino, MD{dagger}, Silvia Pradella, MD, Lorenzo Ghilli, MD{ddagger}, Carlo Rostagno, MD{ddagger}, Gian Franco Gensini, MD, and Carlo Sorbara, MD

*Department of Cardiac Surgery; Careggi Hospital, Florence, Italy; {dagger}Department of Radiology; University of Florence, Florence, Italy; {ddagger}Department of Internal Medicine and Cardiology; University of Florence, Florence, Italy.

Address correspondence and reprint requests to Stefano Romagnoli, MD, Cardiac Surgery Intensive Care, Careggi Hospital, Viale Morgagni 85, 50134, Florence, Italy. Address e-mail to romagnoliste{at}tiscali.it.

Recombinant activated factor VII (rFVIIa) has been used at different doses in cardiac surgery patients. We tested the efficacy of small-dose rFVIIa in patients with intractable bleeding after cardiac surgery. The study group comprised 15 cardiac surgery patients with intractable bleeding treated with small-dose (1.2 mg) rFVIIa as a slow IV bolus at the end of complete step-by step transfusion protocol. Fifteen matched patients undergoing the same transfusion protocol in the pre-rFVIIa era represented the control group. Blood loss at the end of the transfusion protocol was a primary outcome. Median, 25th–75th 24-h blood loss percentiles were 1685 (1590–1770) mL versus 3170 (2700–3850) mL in study group and controls, respectively (P = 0.0004). Transfused red blood cells, fresh-frozen plasma, and platelets in the study group and controls were as follows: 7 (4–8) U versus 18 (12–21) U (P = 0.001); 7.5 (6–11) U versus 11 (9–15) U (P = 0.003); 0 (0–4) U versus 9 (6–13) U (P = 0.001). In addition, significant improvements of prothrombin time (P = 0.015), international normalized ratio (P = 0.006), activated partial prothrombin time (P = 0.01), and platelet count (P = 0.003) were detected in the study group versus controls. Finally, patients receiving rFVIIa showed a reduced intensive care unit length of stay ({chi}2 = 15.9, P = 0.0001) and had infrequent surgical re-exploration ({chi}2 = 16.2,P < 0.0001). Small-dose rFVIIa showed satisfactory results in cardiac patients with intractable bleeding. Further randomized studies are necessary to confirm our findings.




This article has been cited by other articles:


Home page
CirculationHome page
K. Karkouti, W. S. Beattie, R. Arellano, T. Aye, J. S. Bussieres, J. L. Callum, D. Cheng, L. Heinrich, B. Kent, T. W.R. Lee, et al.
Comprehensive Canadian Review of the Off-Label Use of Recombinant Activated Factor VII in Cardiac Surgery
Circulation, July 22, 2008; 118(4): 331 - 338.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
L. J. Bowman, W. E. Uber, M. R. Stroud, L. R. Christiansen, J. Lazarchick, A. J. Crumbley III, J. M. Kratz, J. M. Toole, F. A. Crawford Jr, and J. S. Ikonomidis
Use of Recombinant Activated Factor VII Concentrate to Control Postoperative Hemorrhage in Complex Cardiovascular Surgery.
Ann. Thorac. Surg., May 1, 2008; 85(5): 1669 - 1677.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
S. Dunkley, L. Phillips, P. McCall, J. Brereton, R. Lindeman, G. Jankelowitz, and P. Cameron
Recombinant Activated Factor VII in Cardiac Surgery: Experience From the Australian and New Zealand Haemostasis Registry
Ann. Thorac. Surg., March 1, 2008; 85(3): 836 - 844.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
S. J. Johnson, M. B. Ross, and K. G. Moores
Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery
Am. J. Health Syst. Pharm., September 1, 2007; 64(17): 1808 - 1812.
[Abstract] [Full Text] [PDF]


Home page
Canadian J. AnesthesiaHome page
K. Karkouti, W. S. Beattie, M. A. Crowther, J. L. Callum, R. Chun, S. E. Fremes, J. Lemieux, V. C. McAlister, B. D. Muirhead, J. M. Murkin, et al.
The role of recombinant factor VIIa in on-pump cardiac surgery: Proceedings of the Canadian Consensus Conference: [Le role du facteur VIIa recombinant dans la chirurgie cardiaque avec circulation extra-corporelle : Rapport de la Conference canadienne de consensus]
Can J Anesth, July 1, 2007; 54(7): 573 - 582.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
O. Warren, K. Mandal, V. Hadjianastassiou, L. Knowlton, S. Panesar, K. John, A. Darzi, and T. Athanasiou
Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review
Ann. Thorac. Surg., February 1, 2007; 83(2): 707 - 714.
[Abstract] [Full Text] [PDF]




Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2006 by the International Anesthesia Research Society.